This presentation will summarize the results of a Phase 1 trial of microbiota transplant therapy (MTT) for children with autism, and the results of a new study of MTT for children with Pitt Hopkins. MTT is an investigational therapy involving pretreatment with vancomycin, then a bowel cleanse, and then 8-12 weeks of microbiota from healthy humans. The effect of MTT on gastrointestinal and autism-related symptoms will be presented. This is the first clinical trial ever conducted for Pitt Hopkins.
Speaker: James Adams, PhD